» Articles » PMID: 36226315

Mechanistic Target of Rapamycin Signaling in Human Nervous System Development and Disease

Overview
Specialty Molecular Biology
Date 2022 Oct 13
PMID 36226315
Authors
Affiliations
Soon will be listed here.
Abstract

Mechanistic target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that regulates fundamental cellular processes including growth control, autophagy and metabolism. mTOR has key functions in nervous system development and mis-regulation of mTOR signaling causes aberrant neurodevelopment and neurological diseases, collectively called mTORopathies. In this mini review we discuss recent studies that have deepened our understanding of the key roles of the mTOR pathway in human nervous system development and disease. Recent advances in single-cell transcriptomics have been exploited to reveal specific roles for mTOR signaling in human cortical development that may have contributed to the evolutionary divergence from our primate ancestors. Cerebral organoid technology has been utilized to show that mTOR signaling is active in and regulates outer radial glial cells (RGCs), a population of neural stem cells that distinguish the human developing cortex. mTOR signaling has a well-established role in hamartoma syndromes such as tuberous sclerosis complex (TSC) and other mTORopathies. New ultra-sensitive techniques for identification of somatic mTOR pathway mutations have shed light on the neurodevelopmental origin and phenotypic heterogeneity seen in mTORopathy patients. These emerging studies suggest that mTOR signaling may facilitate developmental processes specific to human cortical development but also, when mis-regulated, cause cortical malformations and neurological disease.

Citing Articles

Chronic Rapamycin Prevents Electrophysiological and Morphological Alterations Produced by Conditional Pten Deletion in Mouse Cortex.

Hauptman J, Antonios J, Mathern G, Levine M, Cepeda C Cells. 2025; 14(2).

PMID: 39851507 PMC: 11764219. DOI: 10.3390/cells14020079.


Drug Treatments for Neurodevelopmental Disorders: Targeting Signaling Pathways and Homeostasis.

Kaufmann W, Luu S, Budimirovic D Curr Neurol Neurosci Rep. 2024; 25(1):7.

PMID: 39641900 DOI: 10.1007/s11910-024-01394-3.


Somatostatin interneuron fate-mapping and structure in a Pten knockout model of epilepsy.

Drake A, Jerow L, Ruksenas J, McCoy C, Danzer S Front Cell Neurosci. 2024; 18:1474613.

PMID: 39497922 PMC: 11532043. DOI: 10.3389/fncel.2024.1474613.


mTOR and neuroinflammation in epilepsy: implications for disease progression and treatment.

Ravizza T, Scheper M, Di Sapia R, Gorter J, Aronica E, Vezzani A Nat Rev Neurosci. 2024; 25(5):334-350.

PMID: 38531962 DOI: 10.1038/s41583-024-00805-1.


Reversal of memory and autism-related phenotypes in mice via inhibition of .

Chalkiadaki K, Statoulla E, Zafeiri M, Haji N, Lacaille J, Powell C Front Cell Dev Biol. 2023; 11:1205112.

PMID: 37293130 PMC: 10244498. DOI: 10.3389/fcell.2023.1205112.


References
1.
Polchi A, Magini A, Meo D, Tancini B, Emiliani C . mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model. Int J Mol Sci. 2018; 19(5). PMC: 5983755. DOI: 10.3390/ijms19051474. View

2.
Giannikou K, Zhu Z, Kim J, Winden K, Tyburczy M, Marron D . Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Mod Pathol. 2020; 34(2):264-279. PMC: 9361192. DOI: 10.1038/s41379-020-00659-9. View

3.
Almecija S, Hammond A, Thompson N, Pugh K, Moya-Sola S, Alba D . Fossil apes and human evolution. Science. 2021; 372(6542). DOI: 10.1126/science.abb4363. View

4.
Catlett T, Onesto M, McCann A, Rempel S, Glass J, Franz D . RHOA signaling defects result in impaired axon guidance in iPSC-derived neurons from patients with tuberous sclerosis complex. Nat Commun. 2021; 12(1):2589. PMC: 8110792. DOI: 10.1038/s41467-021-22770-4. View

5.
Li Y, Cao J, Chen M, Li J, Sun Y, Zhang Y . Abnormal Neural Progenitor Cells Differentiated from Induced Pluripotent Stem Cells Partially Mimicked Development of TSC2 Neurological Abnormalities. Stem Cell Reports. 2017; 8(4):883-893. PMC: 5390135. DOI: 10.1016/j.stemcr.2017.02.020. View